Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 45 | 2022 | 376 | 8.490 |
Why?
|
| Depressive Disorder, Major | 9 | 2022 | 441 | 2.450 |
Why?
|
| Antidepressive Agents | 6 | 2022 | 332 | 1.310 |
Why?
|
| Suicidal Ideation | 4 | 2022 | 207 | 1.140 |
Why?
|
| Affect | 5 | 2021 | 288 | 0.960 |
Why?
|
| Impulsive Behavior | 5 | 2017 | 142 | 0.950 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 5 | 2022 | 92 | 0.860 |
Why?
|
| Endophenotypes | 4 | 2021 | 18 | 0.850 |
Why?
|
| Psychopharmacology | 1 | 2021 | 13 | 0.780 |
Why?
|
| Gyrus Cinguli | 3 | 2021 | 140 | 0.730 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 414 | 0.680 |
Why?
|
| Emotions | 2 | 2021 | 562 | 0.610 |
Why?
|
| Prefrontal Cortex | 3 | 2010 | 229 | 0.610 |
Why?
|
| White Matter | 4 | 2021 | 195 | 0.550 |
Why?
|
| Deep Brain Stimulation | 4 | 2022 | 348 | 0.540 |
Why?
|
| Hippocampus | 3 | 2018 | 915 | 0.520 |
Why?
|
| Cognition Disorders | 4 | 2015 | 786 | 0.500 |
Why?
|
| Mood Disorders | 5 | 2022 | 163 | 0.500 |
Why?
|
| Gonadotropins | 1 | 2013 | 50 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2021 | 7702 | 0.460 |
Why?
|
| Brain | 13 | 2022 | 4113 | 0.450 |
Why?
|
| Students, Medical | 1 | 2018 | 399 | 0.450 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 918 | 0.410 |
Why?
|
| Antimanic Agents | 1 | 2010 | 39 | 0.380 |
Why?
|
| Humans | 59 | 2022 | 261506 | 0.330 |
Why?
|
| Interview, Psychological | 2 | 2021 | 98 | 0.310 |
Why?
|
| Internship and Residency | 1 | 2018 | 1375 | 0.300 |
Why?
|
| Parents | 1 | 2014 | 998 | 0.300 |
Why?
|
| Corpus Striatum | 1 | 2005 | 104 | 0.250 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2022 | 604 | 0.250 |
Why?
|
| Cognition | 3 | 2015 | 968 | 0.240 |
Why?
|
| Substance-Related Disorders | 3 | 2017 | 524 | 0.220 |
Why?
|
| Amygdala | 3 | 2018 | 127 | 0.210 |
Why?
|
| Neuroimaging | 4 | 2022 | 403 | 0.210 |
Why?
|
| Protective Factors | 1 | 2021 | 106 | 0.200 |
Why?
|
| Defense Mechanisms | 1 | 2021 | 22 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 4314 | 0.200 |
Why?
|
| Neurochemistry | 1 | 2020 | 6 | 0.200 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 129 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2018 | 6100 | 0.200 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2021 | 303 | 0.190 |
Why?
|
| Voice Quality | 1 | 2021 | 33 | 0.190 |
Why?
|
| Opiate Alkaloids | 1 | 2020 | 6 | 0.190 |
Why?
|
| Cholinergic Agents | 1 | 2020 | 21 | 0.190 |
Why?
|
| Adult | 24 | 2021 | 77950 | 0.190 |
Why?
|
| Facial Expression | 1 | 2021 | 49 | 0.190 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2021 | 59 | 0.190 |
Why?
|
| GABA Agents | 1 | 2020 | 26 | 0.190 |
Why?
|
| Personality Assessment | 1 | 2021 | 105 | 0.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2022 | 231 | 0.190 |
Why?
|
| Medial Forebrain Bundle | 2 | 2022 | 2 | 0.180 |
Why?
|
| Risk Factors | 6 | 2022 | 17523 | 0.180 |
Why?
|
| Hallucinogens | 1 | 2020 | 48 | 0.180 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 80 | 0.180 |
Why?
|
| Borderline Personality Disorder | 1 | 2022 | 151 | 0.170 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 313 | 0.170 |
Why?
|
| Glutamic Acid | 1 | 2020 | 309 | 0.170 |
Why?
|
| Ketamine | 1 | 2022 | 234 | 0.160 |
Why?
|
| Obesity | 3 | 2015 | 2884 | 0.150 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 1178 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2020 | 369 | 0.150 |
Why?
|
| Brain Mapping | 4 | 2015 | 644 | 0.150 |
Why?
|
| Functional Laterality | 3 | 2008 | 316 | 0.150 |
Why?
|
| Motor Activity | 1 | 2021 | 693 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 945 | 0.140 |
Why?
|
| Reward | 1 | 2017 | 169 | 0.140 |
Why?
|
| Female | 26 | 2021 | 141928 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 488 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 678 | 0.140 |
Why?
|
| Lithium | 1 | 2015 | 71 | 0.140 |
Why?
|
| Adolescent | 13 | 2022 | 31252 | 0.140 |
Why?
|
| Memantine | 1 | 2015 | 46 | 0.130 |
Why?
|
| Mifepristone | 1 | 2015 | 147 | 0.130 |
Why?
|
| Anisotropy | 3 | 2021 | 181 | 0.130 |
Why?
|
| Male | 24 | 2018 | 123000 | 0.130 |
Why?
|
| Benzothiazoles | 1 | 2015 | 94 | 0.130 |
Why?
|
| Frontal Lobe | 2 | 2014 | 187 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 792 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2015 | 110 | 0.130 |
Why?
|
| Child of Impaired Parents | 1 | 2014 | 17 | 0.130 |
Why?
|
| Anxiety | 1 | 2022 | 1179 | 0.130 |
Why?
|
| Family | 1 | 2018 | 736 | 0.120 |
Why?
|
| Speech Disorders | 1 | 2015 | 91 | 0.120 |
Why?
|
| Limbic System | 1 | 2014 | 29 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 4744 | 0.120 |
Why?
|
| Irritable Mood | 1 | 2013 | 12 | 0.120 |
Why?
|
| Lithium Compounds | 1 | 2013 | 15 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 1648 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2014 | 131 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 341 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 130 | 0.110 |
Why?
|
| Machine Learning | 1 | 2016 | 319 | 0.110 |
Why?
|
| Young Adult | 6 | 2018 | 21445 | 0.110 |
Why?
|
| Child | 11 | 2021 | 29154 | 0.110 |
Why?
|
| Depression | 3 | 2022 | 1715 | 0.110 |
Why?
|
| Antioxidants | 1 | 2015 | 507 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2015 | 431 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 901 | 0.100 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2021 | 30 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2011 | 151 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 184 | 0.100 |
Why?
|
| Verbal Learning | 2 | 2014 | 84 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2015 | 557 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 2488 | 0.090 |
Why?
|
| Brain Chemistry | 1 | 2010 | 145 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2010 | 126 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 218 | 0.090 |
Why?
|
| Family Relations | 1 | 2010 | 88 | 0.090 |
Why?
|
| Insulin | 1 | 2015 | 1454 | 0.090 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.090 |
Why?
|
| Social Environment | 1 | 2010 | 176 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2017 | 2307 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 509 | 0.080 |
Why?
|
| Drug Design | 1 | 2010 | 375 | 0.080 |
Why?
|
| Protons | 1 | 2010 | 473 | 0.080 |
Why?
|
| Comorbidity | 3 | 2022 | 2352 | 0.080 |
Why?
|
| Observer Variation | 1 | 2009 | 671 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 5539 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 669 | 0.070 |
Why?
|
| Middle Aged | 9 | 2021 | 86204 | 0.070 |
Why?
|
| Models, Biological | 1 | 2015 | 3254 | 0.070 |
Why?
|
| Putamen | 1 | 2005 | 26 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 6009 | 0.070 |
Why?
|
| Risk-Taking | 2 | 2017 | 133 | 0.070 |
Why?
|
| Caudate Nucleus | 1 | 2005 | 43 | 0.060 |
Why?
|
| Organ Size | 2 | 2018 | 690 | 0.060 |
Why?
|
| Speech Perception | 1 | 2005 | 66 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2522 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1879 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1362 | 0.060 |
Why?
|
| Pituitary Gland | 1 | 2004 | 150 | 0.060 |
Why?
|
| Biomarkers | 1 | 2015 | 5047 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2020 | 192 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2005 | 295 | 0.050 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2022 | 21 | 0.050 |
Why?
|
| Anhedonia | 1 | 2021 | 39 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 75 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2022 | 37905 | 0.050 |
Why?
|
| Functional Neuroimaging | 1 | 2021 | 38 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2020 | 26 | 0.050 |
Why?
|
| Gray Matter | 1 | 2021 | 63 | 0.050 |
Why?
|
| Chemokine CCL11 | 1 | 2020 | 18 | 0.050 |
Why?
|
| Kynurenine | 1 | 2020 | 71 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 674 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2022 | 247 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2020 | 112 | 0.040 |
Why?
|
| Animals | 5 | 2021 | 59536 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 68 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2020 | 80 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 103 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 423 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2021 | 478 | 0.040 |
Why?
|
| Nucleus Accumbens | 1 | 2018 | 61 | 0.040 |
Why?
|
| Cyclothymic Disorder | 1 | 2017 | 3 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 257 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 1144 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2015 | 14 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 44 | 0.030 |
Why?
|
| Cerebellum | 1 | 2018 | 449 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 4320 | 0.030 |
Why?
|
| Alcoholism | 1 | 2017 | 285 | 0.030 |
Why?
|
| Diacylglycerol Kinase | 1 | 2014 | 23 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 202 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2014 | 76 | 0.030 |
Why?
|
| Ankyrins | 1 | 2014 | 104 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 176 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2022 | 32848 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2014 | 298 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 147 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 4109 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6150 | 0.030 |
Why?
|
| Aging | 1 | 2020 | 1582 | 0.030 |
Why?
|
| Glycerylphosphorylcholine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Phosphocreatine | 1 | 2010 | 17 | 0.020 |
Why?
|
| Memory | 1 | 2014 | 429 | 0.020 |
Why?
|
| Inositol | 1 | 2010 | 27 | 0.020 |
Why?
|
| Outpatients | 1 | 2014 | 462 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2010 | 54 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 756 | 0.020 |
Why?
|
| Sex Factors | 2 | 2005 | 2139 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 1084 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 497 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2014 | 666 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 980 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 624 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1945 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2437 | 0.020 |
Why?
|
| United States | 2 | 2015 | 15433 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4298 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 4971 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 7222 | 0.020 |
Why?
|
| Parenting | 1 | 2010 | 345 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 12873 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.020 |
Why?
|
| Reaction Time | 1 | 2005 | 234 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 6311 | 0.020 |
Why?
|
| Mental Recall | 1 | 2005 | 171 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2005 | 160 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2004 | 97 | 0.010 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2004 | 127 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 4549 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 70117 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 5377 | 0.010 |
Why?
|